Patrick Winter, PhD received his undergraduate degree in Electrical Engineering from Washington University in St. Louis, Missouri and his PhD in Biomedical Engineering from The University of Texas Southwestern Medical School in Dallas. Patrick returned to Washington University as a post-doc in 2000 and subsequently became an Assistant Professor of Medicine in 2005. He took a one-year leave of absence from his faculty position in 2008 to initiate clinical trials of an investigational MRI contrast agent with a small bio-technology company in St. Louis named Kereos. In 2010, he joined the Imaging Research Center at Cincinnati Children’s Hospital.
Dr. Winter has more than 15 years of experience in MRI research, with a strong record of publications (51 peer-reviewed journal papers, 13 book chapters and 79 scientific abstracts) and grant funding from the NIH and private sources (4 grants as principal investigator and 5 grants as co-investigator). In addition, Dr. Winter is involved in reviewing journal articles, teaching at university and professional levels, organizing courses and scientific sessions, consulting for pharmaceutical companies and participating in professional societies. His current research interests include molecular imaging of cancer and cardiovascular disease, multi-nuclear imaging and spectroscopy, activatable MRI contrast agents, and automated image processing routines.
Education and Training
PhD: Biomedical Engineering, University of Texas Southwestern Medical School, Dallas, TX, 2000.
BS: Electrical Engineering, Washington University, St. Louis, MO, 1994.
View PubMed Publications
Winter PM, Caruthers SD, Lanza GM, Wickline SA. Quantitative cardiovascular magnetic resonance for molecular imaging. J Cardiovasc Magn Reson. 2010 Nov 3;12:62.
Cai K, Caruthers SD, Huang W, Williams TA, Zhang H, Wickline SA, Lanza GM, Winter PM. MR molecular imaging of aortic angiogenesis. JACC Cardiovasc Imaging. 2010 Aug;3(8):824-32.
Winter PM, Caruthers SD, Allen JS, Cai K, Williams TA, Lanza GM, Wickline SA. Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrin-targeted nanoparticles. Magn Reson Med. 2010 Aug;64(2):369-76.
Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA, Lanza GM. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging. 2008 Sep;1(5):624-34.
Winter PM, Schmieder AH, Caruthers SD, Keene JL, Zhang H, Wickline SA, Lanza GM. Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J. 2008 Aug;22(8):2758-67.
Winter PM, Cai K, Caruthers SD, Wickline SA, Lanza GM. Emerging nanomedicine opportunities with perfluorocarbon nanoparticles. Expert Rev Med Devices. 2007 Mar;4(2):137-45.
Winter PM, Cai K, Chen J, Adair CR, Kiefer GE, Athey PS, Gaffney PJ, Buff CE, Robertson JD, Caruthers SD, Wickline SA, Lanza GM. Targeted PARACEST nanoparticle contrast agent for the detection of fibrin. Magn Reson Med. 2006 Dec;56(6):1384-8.
Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder AH, Hu G, Allen JS, Lacy EK, Zhang H, Wickline SA, Lanza GM. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2103-9.
Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation. 2003 Nov 4;108(18):2270-4.
Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang H, Robertson JD, Wickline SA, Lanza GM. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 2003 Sep 15;63(18):5838-43.